Sulopenem Etzadroxil plus Probenecid (Orlynvah) for Uncomplicated Urinary Tract Infections

Orlynvah is the first oral carbapenem approved for treatment of uUTIs in women.

Sulopenem etzadroxil (SE) is an oral prodrug that is hydrolyzed by intestinal esterases into sulopenem, a carbapenem with in vitro activity against fluoroquinolone-resistant, extended-spectrum β-lactamase (ESBL)–producing, multidrug-resistant Enterobacterales. In vitro studies have shown that sulopenem demonstrates greater activity than meropenem or ertapenem against certain gram-positive bacteria (e.g., Enterococcus faecalis, Listeria monocytogenes, methicillin-susceptible Staphylococcus aureus [MSSA], Staphylococcus epidermidis). Oral bioavailability of SE is 40% (fasting) and 64% (with a high-fat meal). Coadministration with probenecid further enhances SE exposure. The drug will be marketed as Orlynvah bilayer tablets containing 500 mg S…

Author

George Sakoulas, MD

Disclosures

Consultant/Advisory BoardParatek Pharmaceuticals; Nestle Corp.; AbbVie; Shionogi

Speaker’s BureauAllergan/AbbVie; Paratek Pharmaceuticals; Nestle Corp.

RoyaltiesUpToDate

Editorial BoardsAntimicrobial Agents and Chemotherapy; Open Forum Infectious Diseases